{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:37:51Z","timestamp":1793587071695,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-6JG"],"award-info":[{"award-number":["CA209-6JG"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["13226"],"award-info":[{"award-number":["13226"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41591-026-04271-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:02:37Z","timestamp":1772226157000},"page":"1241-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5054-6019","authenticated-orcid":false,"given":"Jan-Jaap J.","family":"Mellema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal F.","family":"Stockem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Herberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha K.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W. G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry N.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits L.","family":"van Montfoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-1895","authenticated-orcid":false,"given":"Sara","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeantine M.","family":"de Feijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes C. K.","family":"van der Mijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"El Naggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-0436","authenticated-orcid":false,"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Franckena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juus L.","family":"Noteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva E.","family":"Schaake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-9991","authenticated-orcid":false,"given":"Debbie G. J.","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt B. M.","family":"Suelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4407-7881","authenticated-orcid":false,"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"4271_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"4271_CR2","doi-asserted-by":"publisher","first-page":"e043266","DOI":"10.1136\/bmjopen-2020-043266","volume":"11","author":"SL Maibom","year":"2021","unstructured":"Maibom, S. L. et al. Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open 11, e043266 (2021).","journal-title":"BMJ Open"},{"key":"4271_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky075","volume":"2","author":"KE Marqueen","year":"2018","unstructured":"Marqueen, K. E. et al. Early mortality in patients with muscle-invasive bladder cancer undergoing cystectomy in the United States. JNCI Cancer Spectr. 2, pky075 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"4271_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","volume":"96","author":"KS Mak","year":"2016","unstructured":"Mak, K. S. et al. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 96, 1028\u20131036 (2016).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"4271_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta, A. R. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 24, 669\u2013681 (2023).","journal-title":"Lancet Oncol."},{"key":"4271_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","volume":"118","author":"K Br\u00fcck","year":"2024","unstructured":"Br\u00fcck, K. et al. Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study. Int. J. Radiat. Oncol. Biol. Phys. 118, 41\u201349 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"4271_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur. Urol. 87, 582\u2013600 (2025).","journal-title":"Eur. Urol."},{"key":"4271_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258 (2022).","journal-title":"Ann. Oncol."},{"key":"4271_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","volume":"36","author":"O Fahmy","year":"2018","unstructured":"Fahmy, O. et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol. Oncol. 36, 43\u201353 (2018).","journal-title":"Urol. Oncol."},{"key":"4271_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","volume":"7","author":"R Kool","year":"2024","unstructured":"Kool, R. et al. Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis. Eur. Urol. Oncol. 7, 1350\u20131357 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"4271_CR11","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","volume":"16","author":"WU Shipley","year":"1998","unstructured":"Shipley, W. U. et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J. Clin. Oncol. 16, 3576\u20133583 (1998).","journal-title":"J. Clin. Oncol."},{"key":"4271_CR12","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med."},{"key":"4271_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","volume":"29","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. 29, 588\u2013592 (2023).","journal-title":"Nat. Med."},{"key":"4271_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115731","volume":"229","author":"CF Stockem","year":"2025","unstructured":"Stockem, C. F. et al. Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: the NABUCCO trial. Eur. J. Cancer 229, 115731 (2025).","journal-title":"Eur. J. Cancer"},{"key":"4271_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James, N. D. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med. 366, 1477\u20131488 (2012).","journal-title":"N. Engl. J. Med."},{"key":"4271_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109584","volume":"183","author":"A de Haar-Holleman","year":"2023","unstructured":"de Haar-Holleman, A. et al. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study. Radiother. Oncol. 183, 109584 (2023).","journal-title":"Radiother. Oncol."},{"key":"4271_CR17","doi-asserted-by":"crossref","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. 393, 2395\u22122408 (2025).","DOI":"10.1056\/NEJMoa2511885"},{"key":"4271_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4271_CR19","doi-asserted-by":"publisher","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","volume":"36","author":"C Vulsteke","year":"2025","unstructured":"Vulsteke, C. et al. LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study. Ann. Oncol. 36, S1648 (2025).","journal-title":"Ann. Oncol."},{"key":"4271_CR20","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. J. Clin. Oncol. 43, 4503 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4271_CR21","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2025.43.16_suppl.4500","volume":"43","author":"MS van der Heijden","year":"2025","unstructured":"van der Heijden, M. S. et al. Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): final results for cisplatin-ineligible patients from the CheckMate 901 trial. J. Clin. Oncol. 43, 4500 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4271_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4271_CR23","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."},{"key":"4271_CR24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1200\/JCO-24-01214","volume":"43","author":"DM Geynisman","year":"2025","unstructured":"Geynisman, D. M. et al. Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1). J. Clin. Oncol. 43, 1113\u20131122 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4271_CR25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04271-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:32:38Z","timestamp":1776857558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4271"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04271-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.v.d.H. has received institutional funding from Bristol Myers Squibb to finance the INDIBLADE trial. C.H., S.K.C., S.S. and A.C.E. are all full-time employee at Natera, Inc. with stocks or options to own stocks in the company. No other author received financial support for the work reported in this paper. No medical writers were involved in drafting the manuscript. B.W.G.v.R. has received consulting fees from Cepheid and Astellas (institutional). L.S.M. received consulting fees from Johnson & Johnson and Merck (institutional). T.N.B. makes use of free-to-use server and software for research purposes from Siemens. J.M.d.F. has an advisory role for Merck and Janssen (institutional). J.C.K.v.d.M. received research support from Bayer (institutional) and received consultancy fees from Merck\/Merck Sharp & Dohme, IPSEN, Jansen, Bayer, Novartis and AstraZeneca (institutional). J.L.B. received consulting fees from Bristol Myers Squibb, Janssen, AstraZeneca, Merck AG\/Pfizer, Merck Sharp & Dohme, Bayer and Ismar Healthcare (institutional) and received speaker\u2019s fees from Springer Media, Congress Care and NLC Health (personal). R.P.M. has an advisory role for Astellas, Merck and Bristol Myers Squibb (institutional) and received research support from Merck, Janssen-Cilag, Astellas and Gilead Sciences Netherlands (institutional). D.G.J.R. has an advisory role for MSD Oncology, Pfizer, Astellas, AstraZeneca, Johnson & Johnson, Merck and Gilead Sciences Netherlands (institutional) and has received research support from Merck (institutional). B.B.M.S. has an advisory role for AstraZeneca, Bristol Myers Squibb, MDS, IPSEN, Merck, Astellas and Pfizer (institutional) and has received research support from AstraZeneca, Bristol Myers Squibb, MDS, IPSEN, Merck, Astellas and Pfizer (institutional). M.S.v.d.H. has received consulting fees from Astellas, AstraZeneca, Bristol Myers Squibb, MSD Oncology, Pfizer\/Seagen, Johnson & Johnson and Daiichi-Sankyo (institutional); has received research support from Bristol Myers Squibb, Roche, AstraZeneca, Seagen, 4SC and MSD Oncology (institutional); and has received travel expenses paid by Bristol Myers Squibb (institutional). All other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}